Advanced
  Home Compare Reports

Comparison with Similar Reports

Companion Animal Pharmaceuticals Market by Indication (Infectious Diseases, Antibiotics, Parasiticides, Vaccines, Pain), Animal Type (Dogs, Cats, Hors...

Publisher:        MarketsandMarkets

# of Pages:        232

Rating: 

1 User License $4,950

Publication Date:  April, 2021

Price:       $4,950 / User License




1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 26
1.2.2 MARKETS COVERED 27
FIGURE 1 COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION 27
1.2.3 YEARS CONSIDERED FOR THE STUDY 27
1.3 CURRENCY 28
TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD 28
1.4 STAKEHOLDERS 28
1.5 LIMITATIONS 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH APPROACH 29
FIGURE 2 RESEARCH DESIGN 29
2.1.1 SECONDARY RESEARCH 30
2.1.1.1 Key data from secondary sources 31
2.1.2 PRIMARY RESEARCH 31
2.1.2.1 Primary sources 32
2.1.2.2 Key data from primary sources 33
2.1.2.3 Key industry insights 34
2.1.2.4 Breakdown of primaries 35
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 35
2.2 MARKET SIZE ESTIMATION 35
FIGURE 4 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 36
FIGURE 5 REVENUE SHARE ANALYSIS ILLUSTRATION: ZOETIS 36
FIGURE 6 SUPPLY-SIDE ANALYSIS OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET 37
FIGURE 7 MARKET ANALYSIS APPROACH 38
FIGURE 8 US: COMPANION ANIMAL PHARMACEUTICALS MARKET APPROACH 39
FIGURE 9 TOP-DOWN APPROACH 39
FIGURE 10 CAGR PROJECTIONS 40
FIGURE 11 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET (2021–2026): IMPACT ON MARKET GROWTH & CAGR 41
2.3 DATA TRIANGULATION APPROACH 43
FIGURE 12 DATA TRIANGULATION METHODOLOGY 43
2.4 MARKET SHARE ESTIMATION 44
2.5 ASSUMPTIONS FOR THE STUDY 44
2.6 RISK ASSESSMENT/LIMITATIONS 45
2.7 COVID-19 HEALTH ASSESSMENT 45
2.8 COVID-19 ECONOMIC ASSESSMENT 45
2.9 ASSESSING THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 46
FIGURE 13 CRITERIA IMPACTING THE GLOBAL ECONOMY 46
FIGURE 14 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 47
3 EXECUTIVE SUMMARY 48
FIGURE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION) 48
FIGURE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2021 VS. 2026 (USD MILLION) 49
FIGURE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2021 VS. 2026 (USD MILLION) 49
FIGURE 18 GEOGRAPHICAL SNAPSHOT OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET 50
4 PREMIUM INSIGHTS 52
4.1 COMPANION ANIMAL PHARMACEUTICALS MARKET OVERVIEW 52
FIGURE 19 RISING PET POPULATION TO DRIVE MARKET GROWTH 52
4.2 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION AND COUNTRY (2020) 53
FIGURE 20 INFECTIOUS DISEASES SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE EUROPEAN MARKET IN 2020 53
4.3 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 54
FIGURE 21 CHINA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 54
4.4 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION (2019–2026) 55
FIGURE 22 NORTH AMERICA WILL CONTINUE TO DOMINATE THE COMPANION ANIMAL PHARMACEUTICALS MARKET DURING THE FORECAST PERIOD 55
4.5 COMPANION ANIMAL PHARMACEUTICALS MARKET: DEVELOPED VS. DEVELOPING MARKETS 55
FIGURE 23 DEVELOPING MARKETS TO REGISTER A HIGHER GROWTH RATE DURING THE FORECAST PERIOD 55
5 MARKET OVERVIEW 56
5.1 INTRODUCTION 56
5.2 MARKET DYNAMICS 56
TABLE 2 COMPANION ANIMAL PHARMACEUTICALS MARKET: IMPACT ANALYSIS 56
5.2.1 MARKET DRIVERS 57
5.2.1.1 Growing prevalence of zoonotic diseases 57
TABLE 3 ANIMAL DISEASE OUTBREAKS IN ASIA PACIFIC COUNTRIES (2013–2018) 57
5.2.1.2 Rising demand for pet insurance with growing animal health expenditure 58
FIGURE 24 US: PET EXPENDITURE, 2010-2019 (USD BILLION) 59
FIGURE 25 US: PET HEALTH INSURANCE MARKET, 2014 VS. 2019 (USD MILLION) 59
5.2.1.3 Growing investments by key players 60
5.2.1.4 Initiatives by various government agencies and animal associations 60
5.2.1.5 Growth in companion animal ownership rates 61
FIGURE 26 DEVELOPED COUNTRIES: PET POPULATION & PET OWNERSHIP 62
5.2.2 MARKET RESTRAINTS 63
5.2.2.1 Rising pet care costs 63
5.2.2.2 Limited number of new product developments 63
5.2.2.3 High storage cost of vaccines 63
5.2.3 MARKET OPPORTUNITIES 64
5.2.3.1 Lucrative growth opportunities in emerging markets 64
5.2.3.2 Growing prevalence of animal diseases 65
5.2.3.3 Technological advancements in manufacturing vaccines 65
5.2.4 MARKET CHALLENGES 66
5.2.4.1 Stringent regulatory approval process for drugs 66
5.2.4.2 Inadequate surveillance and reporting systems of vaccines 66
5.2.4.3 Diversity of parasite species 66
6 INDUSTRY INSIGHTS 67
6.1 INTRODUCTION 67
6.2 INDUSTRY TRENDS 67
6.2.1 GROWING CONSOLIDATION IN THE ANIMAL HEALTHCARE INDUSTRY 67
TABLE 4 MAJOR ACQUISITIONS IN THE ANIMAL HEALTH INDUSTRY (2017–2019) 68
6.2.2 INNOVATIONS IN ANIMAL HEALTHCARE PRODUCTS 68
TABLE 5 INNOVATIVE ANIMAL PHARMACEUTICAL TRENDS 69
6.3 PORTER’S FIVE FORCES ANALYSIS 69
TABLE 6 PORTER’S FIVE FORCES ANALYSIS 69
6.3.1 THREAT OF NEW ENTRANTS 70
6.3.2 THREAT OF SUBSTITUTES 70
6.3.3 BARGAINING POWER OF SUPPLIERS 70
6.3.4 BARGAINING POWER OF BUYERS 71
6.3.5 INTENSITY OF COMPETITIVE RIVALRY 71
6.4 REGULATORY ANALYSIS 71
FIGURE 27 DEVELOPMENT AND APPROVAL PROCESS FOR COMPANION ANIMAL PHARMACEUTICAL PRODUCTS 73
TABLE 7 US: RECENT DEVELOPMENTS IN REGULATIONS FOR VETERINARY DRUGS 74
FIGURE 28 EUROPE: COMPANION ANIMAL PHARMACEUTICAL PRODUCTS APPROVAL PROCESS 75
6.5 VALUE CHAIN ANALYSIS 76
FIGURE 29 COMPANION ANIMAL PHARMACEUTICALS MARKET: VALUE CHAIN ANALYSIS 77
6.6 SUPPLY CHAIN ANALYSIS 77
FIGURE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET: SUPPLY CHAIN ANALYSIS 79
6.7 ECOSYSTEM ANALYSIS 79
6.7.1 ECOSYSTEM ANALYSIS FOR THE COMPANION ANIMAL PHARMACEUTICALS MARKET 79
FIGURE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET: ECOSYSTEM ANALYSIS 80
6.8 IMPACT OF COVID-19 ON THE COMPANION ANIMAL PHARMACEUTICALS MARKET 80
6.9 PATENT ANALYSIS 81
6.9.1 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICALS 81
FIGURE 32 TOP APPLICANTS (COMPANIES/INSTITUTIONS) FOR COMPANION ANIMAL PHARMACEUTICAL PATENTS (2015–2020) 81
6.9.2 TOP INVENTORS FOR COMPANION ANIMAL PHARMACEUTICALS 82
FIGURE 33 TOP INVENTORS FOR COMPANION ANIMAL PHARMACEUTICALS PATENTS (2015–2020) 82
6.9.3 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR COMPANION ANIMAL PHARMACEUTICALS 83
FIGURE 34 TOP APPLICANT COUNTRIES FOR COMPANION ANIMAL PHARMACEUTICAL PATENTS (2015–2020) 83
7 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION 84
7.1 INTRODUCTION 85
TABLE 8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 85
7.2 INFECTIOUS DISEASES 85
TABLE 9 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 86
TABLE 10 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 86
7.2.1 PARASITICIDES 87
7.2.1.1 Growing regulatory guidelines to prevent the spread of parasite-caused diseases is fueling the market growth 87
TABLE 11 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PARASITICIDES, BY COUNTRY, 2019–2026 (USD MILLION) 88
7.2.2 VACCINES 88
7.2.2.1 Rising awareness among pet owners for vaccinating dogs and cats to drive market growth 88
TABLE 12 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VACCINES, BY COUNTRY, 2019–2026 (USD MILLION) 90
7.2.3 ANTIBIOTICS AND ANTIMICROBIALS 90
7.2.3.1 Antibiotics and antimicrobials help combat clinical and subclinical diseases in animals 90
TABLE 13 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ANTIBIOTICS AND ANTIMICROBIALS, BY COUNTRY, 2019–2026 (USD MILLION) 91
7.2.4 OTHER COMPANION ANIMAL PHARMACEUTICALS 92
TABLE 14 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMAL PHARMACEUTICALS, BY COUNTRY, 2019–2026 (USD MILLION) 93
7.3 DERMATOLOGIC DISEASES 93
7.3.1 GROWING CASES OF DERMATOLOGIC DISEASES HAVE INCREASED THE DEMAND FOR VETERINARY PHARMACEUTICALS 93
TABLE 15 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DERMATOLOGIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 94
7.4 PAIN 95
7.4.1 RISING PREVALENCE OF MUSCULOSKELETAL DISORDERS TO DRIVE SUPPORT MARKET GROWTH 95
TABLE 16 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR PAIN, BY COUNTRY, 2019–2026 (USD MILLION) 96
7.5 ORTHOPEDIC DISEASES 96
7.5.1 GROWING PREVALENCE OF OSTEOARTHRITIS AND THE INCREASING POPULATION OF OBESE PETS HAS INCREASED THE DEMAND FOR ORTHOPEDIC DRUGS 96
TABLE 17 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION) 97
7.6 BEHAVIORAL DISORDERS 98
7.6.1 GROWING AWARENESS AMONG PET OWNERS REGARDING BEHAVIORAL DISORDERS IS EXPECTED TO FUEL THE DEMAND FOR THESE DRUGS 98
TABLE 18 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR BEHAVIORAL DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION) 99
7.7 OTHER INDICATIONS 99
TABLE 19 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION) 101
8 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE 102
8.1 INTRODUCTION 103
TABLE 20 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 103
8.2 DOGS 104
8.2.1 DOGS SEGMENT IS EXPECTED TO DOMINATE THE GLOBAL MARKET DURING THE FORECAST PERIOD 104
FIGURE 35 POPULATION OF PET DOGS IN INDIA (MILLION) 104
FIGURE 36 POPULATION OF PET DOGS GLOBALLY (MILLION) 105
TABLE 21 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR DOGS, BY COUNTRY, 2019–2026 (USD MILLION) 106
8.3 CATS 106
8.3.1 GROWING RESEARCH ON FELINE HEALTH AND WELLBEING TO SUPPORT THE MARKET GROWTH 106
TABLE 22 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR CATS, BY COUNTRY, 2019–2026 (USD MILLION) 107
8.4 HORSES 108
8.4.1 RISING PREVALENCE OF INFECTIOUS DISEASES IN THE EQUINE POPULATION TO DRIVE MARKET GROWTH 108
TABLE 23 HORSE POPULATION, BY REGION, 2016–2019 (MILLION) 108
TABLE 24 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR HORSES, BY COUNTRY, 2019–2026 (USD MILLION) 109
8.5 OTHER COMPANION ANIMALS 110
TABLE 25 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR OTHER COMPANION ANIMALS, BY COUNTRY, 2019–2026 (USD MILLION) 110
9 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL 111
9.1 INTRODUCTION 112
TABLE 26 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 112
9.2 VETERINARY HOSPITALS 112
9.2.1 VETERINARY HOSPITALS ARE THE LARGEST AND FASTEST-GROWING SEGMENT OF THE COMPANION ANIMAL PHARMACEUTICALS MARKET 112
TABLE 27 VETERINARY VISIT EXPENSES FOR CATS AND DOGS IN THE US 113
TABLE 28 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION) 113
9.3 VETERINARY CLINICS 114
9.3.1 INCREASING NUMBER OF PRIVATE CLINICAL PRACTICES TO SUPPORT MARKET GROWTH 114
TABLE 29 NUMBER OF PRIVATE CLINICAL PRACTICES, BY COUNTRY, 2015 VS. 2019 115
TABLE 30 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR VETERINARY CLINICS, BY COUNTRY, 2019–2026 (USD MILLION) 116
9.4 RETAIL PHARMACIES 116
9.4.1 EASY ACCESSIBILITY OF PHARMACEUTICALS THROUGH PRESCRIPTION AND OTC TO SUPPORT THE MARKET GROWTH 116
TABLE 31 COMPANION ANIMAL PHARMACEUTICALS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2019–2026 (USD MILLION) 117
10 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION 118
10.1 INTRODUCTION 119
TABLE 32 COMPANION ANIMAL POPULATION, BY COUNTRY, 2020 (THOUSAND) 119
FIGURE 37 COMPANION ANIMAL PHARMACEUTICALS MARKET: GEOGRAPHIC SNAPSHOT 120
TABLE 33 COMPANION ANIMAL PHARMACEUTICALS MARKET, BY REGION, 2019–2026 (USD MILLION) 120
10.2 NORTH AMERICA 121
FIGURE 38 EXPECTED GROWTH IN THE NUMBER OF VETERINARIANS IN NORTH AMERICA 121
FIGURE 39 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT 122
TABLE 34 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 122
TABLE 35 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 123
TABLE 36 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 123
TABLE 37 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 123
TABLE 38 NORTH AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 124
10.2.1 US 124
10.2.1.1 The US dominates the North American companion animal pharmaceuticals market 124
FIGURE 40 US: INCREASE IN PET EXPENDITURE, 2010–2019 (USD BILLION) 124
TABLE 39 US: PRIVATE CLINICAL PRACTICES, BY ANIMAL TYPE, 2016 VS. 2018 125
TABLE 40 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 125
TABLE 41 US: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 126
TABLE 42 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 126
TABLE 43 US: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 126
10.2.2 CANADA 127
10.2.2.1 Increasing pet adoption rate and rising animal health awareness to support market growth in Canada 127
TABLE 44 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 127
TABLE 45 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 128
TABLE 46 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 128
TABLE 47 CANADA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 128
10.3 EUROPE 129
TABLE 48 EUROPE: NUMBER OF VETERINARIANS, 2012–2018 129
TABLE 49 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 130
TABLE 50 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 130
TABLE 51 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 130
TABLE 52 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 131
TABLE 53 EUROPE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 131
10.3.1 GERMANY 131
10.3.1.1 Germany held the largest share of the European market in 2020 131
TABLE 54 GERMANY: COMPANION ANIMAL POPULATION, 2012–2018 (MILLION) 132
TABLE 55 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 132
TABLE 56 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 132
TABLE 57 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 133
TABLE 58 GERMANY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 133
10.3.2 UK 133
10.3.2.1 Growing pet ownership rates to drive market growth 133
TABLE 59 UK: COMPANION ANIMAL POPULATION, 2010–2018 (MILLION) 134
TABLE 60 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 134
TABLE 61 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 135
TABLE 62 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 135
TABLE 63 UK: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 135
10.3.3 FRANCE 136
10.3.3.1 Presence of major players in the country is expected to propel the companion animal pharmaceuticals market 136
TABLE 64 FRANCE: COMPANION ANIMAL POPULATION, 2010–2018 (MILLION) 136
TABLE 65 FRANCE: NUMBER OF VETERINARIANS, 2014 VS. 2016 VS. 2018 137
TABLE 66 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 137
TABLE 67 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 138
TABLE 68 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 138
TABLE 69 FRANCE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 138
10.3.4 SPAIN 139
10.3.4.1 Increasing animal health expenditure is propelling market growth in Spain 139
TABLE 70 SPAIN: COMPANION ANIMAL POPULATION, 2014–2018 (MILLION) 139
TABLE 71 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 139
TABLE 72 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 140
TABLE 73 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 140
TABLE 74 SPAIN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 140
10.3.5 ITALY 141
10.3.5.1 Growing animal healthcare expenditure to support market growth 141
TABLE 75 ITALY: COMPANION ANIMAL POPULATION, 2016–2018 (MILLION) 141
TABLE 76 ITALY: NUMBER OF VETERINARIANS, 2016 VS. 2019 141
TABLE 77 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 142
TABLE 78 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 142
TABLE 79 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 142
TABLE 80 ITALY: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 143
10.3.6 REST OF EUROPE 143
TABLE 81 ROE: COMPANION ANIMAL OWNERSHIP, 2018 (MILLION) 143
TABLE 82 COMPANION ANIMAL POPULATION IN THE REST OF EUROPE, 2019 (MILLION) 144
TABLE 83 ROE: NUMBER OF VETERINARIANS AND PARAVETERINARIANS, 2016 VS. 2019 144
TABLE 84 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 144
TABLE 85 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 145
TABLE 86 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 145
TABLE 87 ROE: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 145
10.4 ASIA PACIFIC 146
FIGURE 41 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET SNAPSHOT 147
TABLE 88 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY COUNTRY, 2019–2026 (USD MILLION) 148
TABLE 89 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 148
TABLE 90 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 148
TABLE 91 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 149
TABLE 92 ASIA PACIFIC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 149
10.4.1 CHINA 149
10.4.1.1 China dominates the companion animal pharmaceuticals market 149
FIGURE 42 CHINA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION) 150
TABLE 93 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 150
TABLE 94 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 151
TABLE 95 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 151
TABLE 96 CHINA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 151
10.4.2 JAPAN 152
10.4.2.1 Rising demand for imported breeds is driving pet adoption rates in the country 152
TABLE 97 JAPAN: NUMBER OF VETERINARIANS, 2016 VS. 2019 152
TABLE 98 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 153
TABLE 99 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 153
TABLE 100 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 153
TABLE 101 JAPAN: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 154
10.4.3 INDIA 154
10.4.3.1 India is an untapped market with large growth potential in companion animal pharmaceuticals 154
FIGURE 43 INDIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION) 155
TABLE 102 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 155
TABLE 103 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 156
TABLE 104 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 156
TABLE 105 INDIA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 156
10.4.4 SOUTH KOREA 157
10.4.4.1 Rising pet population and growing awareness about animal health to support market growth 157
TABLE 106 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 158
TABLE 107 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 158
TABLE 108 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 158
TABLE 109 SOUTH KOREA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 159
10.4.5 REST OF ASIA PACIFIC 159
FIGURE 44 AUSTRALIA: PROJECTED COMPANION ANIMAL POPULATION, 2018–2025 (MILLION) 160
TABLE 110 ROAPAC: NUMBER OF VETERINARIANS, 2012−2019 160
TABLE 111 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 161
TABLE 112 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 161
TABLE 113 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 161
TABLE 114 ROAPAC: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 162
10.5 LATIN AMERICA 162
10.5.1 RISING POOL OF SKILLED VETERINARIANS AND GROWING PET HEALTH EXPENDITURE TO DRIVE THE MARKET GROWTH 162
TABLE 115 NUMBER OF VETERINARIANS AND VETERINARY PARA-PROFESSIONALS IN LATIN AMERICAN COUNTRIES, 2016 VS. 2019 163
TABLE 116 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 163
TABLE 117 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 164
TABLE 118 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 164
TABLE 119 LATIN AMERICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 164
10.6 MIDDLE EAST & AFRICA 165
10.6.1 GROWING POPULATION OF COMPANION ANIMALS TO PROPEL MARKET GROWTH 165
TABLE 120 AFRICA: NUMBER OF VETERINARIANS, 2012 VS. 2017 VS. 2019 166
TABLE 121 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY INDICATION, 2019–2026 (USD MILLION) 166
TABLE 122 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET FOR INFECTIOUS DISEASES, BY TYPE, 2019–2026 (USD MILLION) 166
TABLE 123 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY ANIMAL TYPE, 2019–2026 (USD MILLION) 167
TABLE 124 MIDDLE EAST & AFRICA: COMPANION ANIMAL PHARMACEUTICALS MARKET, BY DISTRIBUTION CHANNEL, 2019–2026 (USD MILLION) 167
11 COMPETITIVE LANDSCAPE 168
11.1 OVERVIEW 168
11.2 KEY PLAYER STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY 2017 TO FEBRUARY 2021 169
11.3 GEOGRAPHICAL FOOTPRINT OF THE MAJOR PLAYERS IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET 170
FIGURE 45 GEOGRAPHIC REVENUE MIX: COMPANION ANIMAL PHARMACEUTICALS MARKET (2020) 170
11.4 COMPANY PRODUCT FOOTPRINT 170
FIGURE 46 PRODUCT PORTFOLIO ANALYSIS: COMPANION ANIMAL PHARMACEUTICALS MARKET 171
11.5 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS 171
FIGURE 47 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE COMPANION ANIMAL PHARMACEUTICALS MARKET (2015–2019) 172
11.6 MARKET SHARE ANALYSIS 172
FIGURE 48 COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2020 173
11.7 MARKET EVALUATION FRAMEWORK 174
FIGURE 49 MARKET EVALUATION FRAMEWORK: ACQUISITIONS—THE MOST WIDELY ADOPTED STRATEGY 174
11.8 COMPETITIVE LEADERSHIP MAPPING 175
11.8.1 STARS 175
11.8.2 EMERGING LEADERS 175
11.8.3 PERVASIVE PLAYERS 176
11.8.4 PARTICIPANTS 176
FIGURE 50 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPETITIVE LEADERSHIP MAPPING (2020) 177
11.9 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS 178
11.9.1 PROGRESSIVE COMPANIES 178
11.9.2 DYNAMIC COMPANIES 178
11.9.3 STARTING BLOCKS 178
11.9.4 RESPONSIVE COMPANIES 178
FIGURE 51 COMPANION ANIMAL PHARMACEUTICALS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2020) 179
11.10 COMPETITIVE SITUATION AND TRENDS 180
11.10.1 PRODUCT LAUNCHES & APPROVALS 180
TABLE 125 PRODUCT LAUNCHES & APPROVALS 180
11.10.2 EXPANSIONS 181
TABLE 126 EXPANSIONS 181
11.10.3 ACQUISITIONS 182
TABLE 127 ACQUISITIONS 182
11.10.4 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 183
TABLE 128 AGREEMENTS, COLLABORATIONS, AND PARTNERSHIPS 183
12 COMPANY PROFILES 185
12.1 KEY PLAYERS 185
(Business Overview, Products Offered, Recent Developments, MnM View)*
12.1.1 ZOETIS INC. 185
TABLE 129 ZOETIS INC.: BUSINESS OVERVIEW 185
FIGURE 52 ZOETIS: COMPANY SNAPSHOT (2020) 186
12.1.2 MERCK & CO., INC. 190
TABLE 130 MERCK & CO., INC.: BUSINESS OVERVIEW 190
FIGURE 53 MERCK & CO., INC.: COMPANY SNAPSHOT (2020) 191
12.1.3 BOEHRINGER INGELHEIM GMBH 194
TABLE 131 BOEHRINGER INGELHEIM GMBH: BUSINESS OVERVIEW 194
FIGURE 54 BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT (2019) 194
12.1.4 ELANCO ANIMAL HEALTH INCORPORATED 198
TABLE 132 ELANCO ANIMAL HEALTH INCORPORATED: BUSINESS OVERVIEW 198
FIGURE 55 ELANCO ANIMAL HEALTH INCORPORATED: COMPANY SNAPSHOT (2019) 199
12.1.5 CEVA SANTÉ ANIMALE 203
TABLE 133 CEVA SANTÉ ANIMALE: BUSINESS OVERVIEW 203
12.1.6 VIRBAC 205
TABLE 134 VIRBAC: BUSINESS OVERVIEW 205
FIGURE 56 VIRBAC: COMPANY SNAPSHOT (2019) 205
12.1.7 VETOQUINOL S.A. 208
TABLE 135 VETOQUINOL S.A.: BUSINESS OVERVIEW 208
FIGURE 57 VETOQUINOL S.A.: COMPANY SNAPSHOT (2019) 208
12.1.8 DECHRA PHARMACEUTICALS PLC 211
TABLE 136 DECHRA PHARMACEUTICALS PLC: BUSINESS OVERVIEW 211
FIGURE 58 DECHRA PHARMACEUTICALS PLC: COMPANY SNAPSHOT (2019) 212
12.1.9 CHANELLE PHARMA 215
TABLE 137 CHANELLE PHARMA: BUSINESS OVERVIEW 215
12.1.10 KYORITSU SEIYAKU 217
TABLE 138 KYORITSU SEIYAKU: BUSINESS OVERVIEW 217
12.1.11 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED 219
TABLE 139 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED: BUSINESS OVERVIEW 219
FIGURE 59 ZYDUS ANIMAL HEALTH AND INVESTMENTS LIMITED: COMPANY SNAPSHOT (2019) 219
12.1.12 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD. 221
TABLE 140 TIANJIN RINGPU BIO-TECHNOLOGY CO., LTD.: BUSINESS OVERVIEW 221
12.1.13 HIPRA 222
TABLE 141 HIPRA: BUSINESS OVERVIEW 222
12.1.14 NORBROOK HOLDINGS LIMITED 223
TABLE 142 NORBROOK HOLDINGS LIMITED: BUSINESS OVERVIEW 223
12.1.15 INOVET 225
TABLE 143 INOVET: BUSINESS OVERVIEW 225
12.2 OTHER PLAYERS 227
12.2.1 ENDOVAC ANIMAL HEALTH 227
12.2.2 ECO ANIMAL HEALTH GROUP PLC 227
12.2.3 INDIAN IMMUNOLOGICALS LTD. 228
12.2.4 ASHISH LIFE SCIENCE PVT. LTD. 229
12.2.5 LUTIM PHARMA PVT. LTD. 230
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
13 APPENDIX 231
13.1 INSIGHTS FROM INDUSTRY EXPERTS 231
13.2 DISCUSSION GUIDE 232
13.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 235
13.4 AVAILABLE CUSTOMIZATIONS 237
13.5 RELATED REPORTS 237
13.6 AUTHOR DETAILS 238

Lateral Flow Assay Components Market by Type, Application Type (Clinical Testing (Infectious, Cardiac Marker Test) Veterinary, Food Safety), Technique...

Publisher:        MarketsandMarkets

# of Pages:        224

Rating: 

1 User License $4,950

Publication Date:  April, 2022

Price:       $4,950 / User License




1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.2.1 CATEGORY-WISE INCLUSIONS AND EXCLUSIONS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 33
1.3 MARKET SCOPE 34
1.3.1 MARKETS COVERED 34
FIGURE 1 LATERAL FLOW ASSAY COMPONENTS MARKET SEGMENTATION 34
1.3.2 YEARS CONSIDERED FOR THE STUDY 35
1.4 CURRENCY 35
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 35
1.5 STAKEHOLDERS 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY DATA 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY DATA 38
2.1.2.1 Primary sources 38
2.1.2.2 Key data from primary sources 39
2.1.2.3 Breakdown of primaries 39
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE):
BY COMPANY TYPE, DESIGNATION, AND REGION 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY END USER, DESIGNATION, AND REGION 40
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021) 41
FIGURE 6 SUPPLY-SIDE ANALYSIS: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 42
2.3 MARKET BREAKDOWN & DATA TRIANGULATION 44
FIGURE 7 DATA TRIANGULATION METHODOLOGY 45
2.4 KEY INDUSTRY INSIGHTS 46
2.5 LIMITATIONS 46
2.5.1 METHODOLOGY-RELATED LIMITATIONS 46
2.6 RISK ASSESSMENT 47
2.7 ASSUMPTIONS FOR THE STUDY 47
 
3 EXECUTIVE SUMMARY 48
FIGURE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2022 VS. 2027 (USD MILLION) 48
FIGURE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2022 VS. 2027 (USD MILLION) 49
FIGURE 10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2022 VS. 2027 (USD MILLION) 50
FIGURE 11 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2022 VS. 2027 (USD MILLION) 51
FIGURE 12 GEOGRAPHICAL SNAPSHOT OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 52
4 PREMIUM INSIGHTS 53
4.1 LATERAL FLOW ASSAY COMPONENTS MARKET OVERVIEW 53
FIGURE 13 RISING NUMBER OF LOCAL MANUFACTURERS FOR COMPONENTS IS DRIVING THE GROWTH OF THE LATERAL FLOW ASSAY COMPONENTS MARKET 53
4.2 REGIONAL MIX: LATERAL FLOW ASSAY COMPONENTS MARKET 54
FIGURE 14 APAC TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD 54
4.3 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE AND COUNTRY 55
FIGURE 15 MEMBRANES ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 55
4.4 LATERAL FLOW ASSAY COMPONENTS MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 56
4.5 LATERAL FLOW ASSAY COMPONENTS MARKET: DEVELOPED VS. DEVELOPING COUNTRIES 56
5 MARKET OVERVIEW 57
5.1 INTRODUCTION 57
5.2 MARKET DYNAMICS: IMPACT ANALYSIS 57
5.2.1 DRIVERS 58
5.2.1.1 Growing demand for lateral flow assay kits due
to the COVID-19 pandemic 58
5.2.1.2 Growing usage of home-based lateral flow assay devices 58
5.2.1.3 Growing demand for point-of-care testing 58
5.2.1.4 Increasing public-private investments to develop lateral flow assays 59
5.2.2 RESTRAINTS 59
5.2.2.1 Availability of alternative diagnostic technologies 59
5.2.3 OPPORTUNITIES 59
5.2.3.1 Evolving applications of lateral flow assays 59
5.2.4 CHALLENGES 60
5.2.4.1 Requirement of specialized storage and shipping facilities for membranes 60
5.3 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES (YC-YCC) IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 60
FIGURE 16 YC–YCC SHIFT IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 61
5.5 AVERAGE SELLING PRICE TREND 61
TABLE 2 AVERAGE SELLING PRICE OF LATERAL FLOW ASSAY COMPONENTS,
BY REGION, 2021 (USD) 61
5.6 ECOSYSTEM MARKET MAP 62
FIGURE 17 ECOSYSTEM: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 62
5.7 PATENT ANALYSIS 63
5.7.1 PATENT PUBLICATION TRENDS FOR LATERAL FLOW ASSAYS 63
FIGURE 18 GLOBAL PATENT PUBLICATION TRENDS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2016–2021 64
5.7.2 JURISDICTION ANALYSIS: TOP APPLICANTS (COUNTRIES) FOR PATENTS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 64
FIGURE 19 JURISDICTION ANALYSIS: TOP APPLICANT COUNTRIES FOR LATERAL FLOW ASSAYS COMPONENTS, 2016–2021 64
5.8 VALUE CHAIN ANALYSIS 65
5.9 REGULATORY LANDSCAPE 66
TABLE 3 REGULATORY STANDARDS/APPROVALS REQUIRED FOR LATERAL FLOW IMMUNOASSAY PRODUCTS, BY COUNTRY/REGION 66
5.9.1 NORTH AMERICA 66
5.9.2 EUROPE 67
5.9.3 ASIA PACIFIC 67
5.9.3.1 India 67
5.9.3.2 China 67
5.9.3.3 Japan 68
5.10 TECHNOLOGY ANALYSIS 69
5.10.1 KEY TECHNOLOGY: LATERAL FLOW ASSAYS 69
5.11 KEY CONFERENCES & EVENTS DURING 2021–2023 69
TABLE 4 LATERAL FLOW ASSAY COMPONENTS MARKET: DETAILED LIST OF CONFERENCES & EVENTS 69
5.12 KEY STAKEHOLDERS & BUYING CRITERIA 70
5.12.1 KEY STAKEHOLDERS IN THE BUYING PROCESS 70
FIGURE 20 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
TABLE 5 INFLUENCE OF STAKEHOLDERS IN THE BUYING PROCESS FOR THE TOP 3 APPLICATIONS 70
5.12.2 BUYING CRITERIA 71
FIGURE 21 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
TABLE 6 KEY BUYING CRITERIA FOR THE TOP 3 APPLICATIONS 71
5.13 PORTER’S FIVE FORCES ANALYSIS 72
TABLE 7 LATERAL FLOW ASSAY COMPONENTS MARKET:
PORTER’S FIVE FORCES ANALYSIS 72
5.13.1 THREAT FROM NEW ENTRANTS 72
5.13.2 THREAT FROM SUBSTITUTES 72
5.13.3 BARGAINING POWER OF BUYERS 73
5.13.4 BARGAINING POWER OF SUPPLIERS 73
5.13.5 INTENSITY OF COMPETITIVE RIVALRY 73
6 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE 74
6.1 INTRODUCTION 75
TABLE 8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 75
6.2 MEMBRANES 75
TABLE 9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE,
2020–2027 (USD MILLION) 76
TABLE 10 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 76
6.2.1 NITROCELLULOSE MEMBRANES 77
6.2.1.1 Advantages of nitrocellulose membranes such as high protein-binding affinity and compatibility with a wide range of detection methods to drive market growth 77
TABLE 11 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES, BY COUNTRY, 2020–2027 (USD MILLION) 77
TABLE 12 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (1 X 1 M SHEETS), BY REGION, 2020–2027 (IN THOUSANDS) 78
TABLE 13 LATERAL FLOW ASSAY COMPONENTS MARKET FOR NITROCELLULOSE MEMBRANES (20 MM X 1 M ROLLS), BY REGION, 2020–2027 (IN MILLIONS) 78
6.2.2 OTHER MEMBRANES 78
TABLE 14 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER MEMBRANES,
BY COUNTRY, 2020–2027 (USD MILLION) 79
6.3 PADS 80
TABLE 15 EXAMPLES OF DIFFERENT MATERIALS USED IN MANUFACTURING LATERAL FLOW ASSAY PADS 80
TABLE 16 LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 80
TABLE 17 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PADS, BY COUNTRY, 2020–2027 (USD MILLION) 81
6.3.1 SAMPLE PADS 81
6.3.1.1 Ability to promote even and controlled distribution of samples to drive market growth 81
TABLE 18 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SAMPLE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 82
6.3.2 CONJUGATE PADS 82
6.3.2.1 Conjugate pads play an important role in controlling the performance of lateral flow immunoassays 82
TABLE 19 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CONJUGATE PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 83
6.3.3 ABSORBENT PADS 84
6.3.3.1 Absorbent pads prevent backflow—a key factor driving market growth 84
TABLE 20 LATERAL FLOW ASSAY COMPONENTS MARKET FOR ABSORBENT PADS,
BY COUNTRY, 2020–2027 (USD MILLION) 84
6.4 OTHER COMPONENTS 84
TABLE 21 OTHER LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 85
7 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION 86
7.1 INTRODUCTION 87
TABLE 22 LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 87
7.2 CLINICAL TESTING 87
TABLE 23 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 24 LATERAL FLOW ASSAYS MARKET FOR CLINICAL TESTING APPLICATIONS,
BY COUNTRY, 2020–2027 (USD MILLION) 88
7.2.1 INFECTIOUS DISEASE TESTING 89
7.2.1.1 Rising demand for infectious disease testing in emerging markets to drive market growth 89
TABLE 25 LATERAL FLOW ASSAY COMPONENTS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 89
7.2.2 PREGNANCY & FERTILITY TESTING 90
7.2.2.1 Growing infertility levels due to changing lifestyles—a key factor driving market growth 90
TABLE 26 LATERAL FLOW ASSAY COMPONENTS MARKET FOR PREGNANCY & FERTILITY TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 90
7.2.3 CARDIAC MARKER TESTING 91
7.2.3.1 Rising prevalence of cardiovascular diseases and growing government support to drive growth in this market segment 91
TABLE 27 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CARDIAC MARKER TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 92
7.2.4 CHOLESTEROL TESTING/LIPID PROFILING 92
7.2.4.1 Growing prevalence of obesity and CVD—
a key factor driving market growth 92
TABLE 28 LATERAL FLOW ASSAY COMPONENTS MARKET FOR CHOLESTEROL TESTING/LIPID PROFILING, BY COUNTRY, 2020–2027 (USD MILLION) 93
7.2.5 DRUGS-OF-ABUSE TESTING 93
7.2.5.1 Technological advancements and a growing focus on workplace
drug testing are driving market growth 93
TABLE 29 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUGS-OF-ABUSE TESTING, BY COUNTRY, 2020–2027 (USD MILLION) 94
7.2.6 OTHER CLINICAL TESTING APPLICATIONS 94
TABLE 30 LATERAL FLOW ASSAY COMPONENTS MARKET FOR OTHER CLINICAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 95
7.3 VETERINARY DIAGNOSTICS 95
7.3.1 INFECTIOUS DISEASE OUTBREAKS (PARTICULARLY IN LARGE LIVESTOCK ANIMALS) TO DRIVE MARKET GROWTH 95
TABLE 31 LATERAL FLOW ASSAY COMPONENTS MARKET FOR VETERINARY DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 96
7.4 FOOD SAFETY & ENVIRONMENTAL TESTING 96
7.4.1 HIGH SENSITIVITY AND EASE OF USE ARE KEY FACTORS DRIVING THE DEMAND FOR LATERAL FLOW ASSAYS FOR FOOD SAFETY TESTING 96
TABLE 32 LATERAL FLOW ASSAY COMPONENTS MARKET FOR FOOD SAFETY & ENVIRONMENTAL TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 97
7.5 DRUG DEVELOPMENT & QUALITY TESTING 97
7.5.1 INCREASING FOCUS ON PRODUCT SAFETY AND QUALITY ASSURANCE TO DRIVE MARKET GROWTH IN THE COMING YEARS 97
TABLE 33 LATERAL FLOW ASSAY COMPONENTS MARKET FOR DRUG DEVELOPMENT & QUALITY TESTING APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 98
8 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE 99
8.1 INTRODUCTION 100
TABLE 34 LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 100
8.2 SANDWICH ASSAYS 100
8.2.1 SANDWICH ASSAYS PROVIDE HIGHER LEVELS OF ASSAY SENSITIVITY AND SPECIFICITY THAN OTHER ASSAY TECHNIQUES—A KEY FACTOR DRIVING GROWTH IN THIS MARKET SEGMENT 100
TABLE 35 LATERAL FLOW ASSAY COMPONENTS MARKET FOR SANDWICH ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 101
8.3 COMPETITIVE ASSAYS 101
8.3.1 REDUCED SELECTIVITY AND SENSITIVITY OF COMPETITIVE ASSAYS IN RELATION TO SANDWICH ASSAYS COULD HAMPER MARKET GROWTH 101
TABLE 36 LATERAL FLOW ASSAY COMPONENTS MARKET FOR COMPETITIVE ASSAYS,
BY COUNTRY, 2020–2027 (USD MILLION) 102
8.4 MULTIPLEX DETECTION ASSAYS 102
8.4.1 INCREASING ADOPTION OF MULTI-ANALYTE ASSAYS AMONG CLINICIANS TO DRIVE MARKET GROWTH 102
TABLE 37 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MULTIPLEX DETECTION ASSAYS, BY COUNTRY, 2020–2027 (USD MILLION) 103
9 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER 104
9.1 INTRODUCTION 105
TABLE 38 LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 105
9.2 MEDICAL DEVICE MANUFACTURING COMPANIES 105
9.2.1 INCREASING USE OF POC TESTS IS DRIVING THE ADOPTION OF LATERAL FLOW ASSAY COMPONENTS AMONG MEDICAL DEVICE MANUFACTURING COMPANIES 105
TABLE 39 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE MANUFACTURING COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 106
9.3 MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES 106
9.3.1 GROWING INCLINATION TOWARD FAST AND EARLY DIAGNOSIS, ESPECIALLY IN RELATION TO THE CURRENT COVID-19 SCENARIO, WILL DRIVE MARKET GROWTH 106
TABLE 40 LATERAL FLOW ASSAY COMPONENTS MARKET FOR MEDICAL DEVICE CONTRACT MANUFACTURING COMPANIES, BY COUNTRY,
2020–2027 (USD MILLION) 107
 
10 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION 108
10.1 INTRODUCTION 109
FIGURE 22 CHINA TO REGISTER THE HIGHEST GROWTH IN THE LATERAL FLOW ASSAY COMPONENTS MARKET DURING THE FORECAST PERIOD 109
TABLE 41 LATERAL FLOW ASSAY COMPONENTS MARKET, BY REGION,
2020–2027 (USD MILLION) 110
10.2 NORTH AMERICA 110
TABLE 42 NORTH AMERICA: MACROECONOMIC INDICATORS 110
FIGURE 23 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 111
TABLE 43 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY COUNTRY, 2020–2027 (USD MILLION) 112
TABLE 44 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 112
TABLE 45 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 112
TABLE 46 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 113
TABLE 47 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 113
TABLE 48 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 114
TABLE 49 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 114
TABLE 50 NORTH AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 115
10.2.1 US 115
10.2.1.1 Increasing R&D investments and venture capital funding from both large and small firms towards the development of lateral flow assay diagnostics to drive market growth in the US 115
TABLE 51 US: MACROECONOMIC INDICATORS 116
TABLE 52 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 116
TABLE 53 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 116
TABLE 54 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 117
TABLE 55 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 117
TABLE 56 US: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 118
TABLE 57 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 118
TABLE 58 US: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 119
10.2.2 CANADA 119
10.2.2.1 Lateral flow assay components market in Canada is estimated to grow at a relatively lower rate than the US 119
TABLE 59 CANADA: MACROECONOMIC INDICATORS 119
TABLE 60 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 120
TABLE 61 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 120
TABLE 62 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 120
TABLE 63 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 121
TABLE 64 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 121
TABLE 65 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 122
TABLE 66 CANADA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 122
10.3 EUROPE 122
TABLE 67 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 123
TABLE 68 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 123
TABLE 69 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 123
TABLE 70 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 124
TABLE 71 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 124
TABLE 72 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 125
TABLE 73 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 125
TABLE 74 EUROPE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 126
10.3.1 GERMANY 126
10.3.1.1 Growing demand for POC testing to drive the lateral flow assay components market in Germany 126
TABLE 75 GERMANY: MACROECONOMIC INDICATORS 126
TABLE 76 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 127
TABLE 77 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 127
TABLE 78 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 127
TABLE 79 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 128
TABLE 80 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
TABLE 81 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 129
TABLE 82 GERMANY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 129
10.3.2 FRANCE 129
10.3.2.1 High prevalence of age-related chronic diseases and infectious diseases to drive market growth in France 129
TABLE 83 FRANCE: MACROECONOMIC INDICATORS 130
TABLE 84 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 130
TABLE 85 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 130
TABLE 86 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 131
TABLE 87 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 131
TABLE 88 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 132
TABLE 89 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 132
TABLE 90 FRANCE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 133
10.3.3 UK 133
10.3.3.1 Severe impact of the second wave of COVID-19 in the first half of 2021 resulted in higher adoption of rapid COVID tests in the UK 133
TABLE 91 UK: MACROECONOMIC INDICATORS 134
TABLE 92 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 134
TABLE 93 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 134
TABLE 94 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 135
TABLE 95 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION,
2020–2027 (USD MILLION) 135
TABLE 96 UK: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 136
TABLE 97 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 136
TABLE 98 UK: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 137
10.3.4 ITALY 137
10.3.4.1 Growing initiatives towards decentralization of medical services in Italy are contributing to the market growth in the country 137
TABLE 99 ITALY: MACROECONOMIC INDICATORS 137
TABLE 100 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 138
TABLE 101 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 138
TABLE 102 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 138
TABLE 103 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 139
TABLE 104 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 139
TABLE 105 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 140
TABLE 106 ITALY: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 140
10.3.5 SPAIN 140
10.3.5.1 Increasing focus of international organizations and domestic players on the development of POC products in the country to drive market growth 140
TABLE 107 SPAIN: MACROECONOMIC INDICATORS 141
TABLE 108 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 141
TABLE 109 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 142
TABLE 110 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 142
TABLE 111 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 142
TABLE 112 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 143
TABLE 113 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 143
TABLE 114 SPAIN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 144
10.3.6 REST OF EUROPE 144
TABLE 115 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 144
TABLE 116 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 145
TABLE 117 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 145
TABLE 118 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 145
TABLE 119 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 146
TABLE 120 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 146
TABLE 121 ROE: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 147
10.4 ASIA PACIFIC 147
FIGURE 24 ASIA PACIFIC: LATERAL FLOW ASSAY COMPONENTS MARKET SNAPSHOT 148
TABLE 122 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 149
TABLE 123 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 149
TABLE 124 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 149
TABLE 125 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 150
TABLE 126 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 150
TABLE 127 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 151
TABLE 128 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 151
TABLE 129 APAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 152
10.4.1 CHINA 152
10.4.1.1 Higher exports of lateral flow assay components during the COVID-19 pandemic to drive market growth in the country 152
TABLE 130 CHINA: MACROECONOMIC INDICATORS 153
TABLE 131 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 153
TABLE 132 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 153
TABLE 133 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 154
TABLE 134 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 154
TABLE 135 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 155
TABLE 136 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 155
TABLE 137 CHINA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 156
10.4.2 JAPAN 156
10.4.2.1 Increasing prevalence of age-related illnesses driving the growth of the lateral flow assay components market in Japan 156
TABLE 138 JAPAN: MACROECONOMIC INDICATORS 157
TABLE 139 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 157
TABLE 140 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 157
TABLE 141 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 158
TABLE 142 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 158
TABLE 143 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 159
TABLE 144 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 159
TABLE 145 JAPAN: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 160
10.4.3 INDIA 160
10.4.3.1 Increasing number of local manufacturers, growing healthcare concerns, and rising income levels to propel the growth of this market 160
TABLE 146 INDIA: MACROECONOMIC INDICATORS 160
TABLE 147 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 161
TABLE 148 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 161
TABLE 149 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE,
2020–2027 (USD MILLION) 161
TABLE 150 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 162
TABLE 151 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 162
TABLE 152 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE,
2020–2027 (USD MILLION) 163
TABLE 153 INDIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER,
2020–2027 (USD MILLION) 163
10.4.4 AUSTRALIA 164
10.4.4.1 Increasing prevalence of infectious diseases, especially influenza, to drive the growth of the lateral flow assay components market in Australia 164
TABLE 154 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 164
TABLE 155 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 164
TABLE 156 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 165
TABLE 157 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 165
TABLE 158 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 166
TABLE 159 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 166
TABLE 160 AUSTRALIA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 167
10.4.5 REST OF ASIA PACIFIC 167
TABLE 161 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE,
2020–2027 (USD MILLION) 167
TABLE 162 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 168
TABLE 163 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD TYPE, 2020–2027 (USD MILLION) 168
TABLE 164 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 168
TABLE 165 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 166 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TECHNIQUE, 2020–2027 (USD MILLION) 169
TABLE 167 ROAPAC: LATERAL FLOW ASSAY COMPONENTS MARKET, BY END USER, 2020–2027 (USD MILLION) 170
 
10.5 LATIN AMERICA 170
10.5.1 HIGH DEMAND FOR HIV POC DEVICES IN THE REGION TO SUPPORT THE GROWTH OF THE MARKET 170
TABLE 168 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 169 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 171
TABLE 170 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET, BY PAD
TYPE, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 172
TABLE 172 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 172
TABLE 173 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 173
TABLE 174 LATIN AMERICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 173
10.6 MIDDLE EAST & AFRICA 173
10.6.1 SIGNIFICANT SUPPORT FROM GOVERNMENTS AND GLOBAL FIRMS TOWARDS EXPANDING HEALTHCARE SERVICES DRIVES THE ADOPTION OF LATERAL FLOW ASSAYS 173
TABLE 175 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS 174
TABLE 176 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TYPE, 2020–2027 (USD MILLION) 174
TABLE 177 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY MEMBRANE TYPE, 2020–2027 (USD MILLION) 175
TABLE 178 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY PAD TYPE, 2020–2027 (USD MILLION) 175
TABLE 179 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY APPLICATION, 2020–2027 (USD MILLION) 175
TABLE 180 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET FOR CLINICAL TESTING APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 181 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY TECHNIQUE, 2020–2027 (USD MILLION) 176
TABLE 182 MIDDLE EAST & AFRICA: LATERAL FLOW ASSAY COMPONENTS MARKET,
BY END USER, 2020–2027 (USD MILLION) 177
11 COMPETITIVE LANDSCAPE 178
11.1 OVERVIEW 178
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 178
FIGURE 25 OVERVIEW OF STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
11.3 REVENUE SHARE ANALYSIS FOR KEY PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 179
FIGURE 26 REVENUE SHARE ANALYSIS FOR THE KEY PLAYERS
IN THE LATERAL FLOW ASSAY COMPONENTS MARKET 180
11.4 MARKET SHARE ANALYSIS 180
FIGURE 27 LATERAL FLOW ASSAY COMPONENTS MARKET SHARE ANALYSIS, BY KEY PLAYER (2021) 181
TABLE 183 LATERAL FLOW ASSAY COMPONENTS MARKET: DEGREE OF COMPETITION 182
11.5 R&D ASSESSMENT OF KEY PLAYERS 183
FIGURE 28 R&D EXPENDITURE: MAJOR PLAYERS IN THE LATERAL FLOW ASSAY COMPONENTS MARKET, 2018 VS. 2020 183
11.6 GEOGRAPHIC REVENUE ASSESSMENT OF KEY PLAYERS 183
FIGURE 29 GEOGRAPHIC REVENUE ASSESSMENT: LATERAL FLOW ASSAY COMPONENTS MARKET (2021) 184
11.7 COMPANY EVALUATION QUADRANT 184
11.7.1 STARS 184
11.7.2 PERVASIVE PLAYERS 184
11.7.3 EMERGING LEADERS 185
11.7.4 PARTICIPANTS 185
FIGURE 30 LATERAL FLOW ASSAY COMPONENTS MARKET: COMPANY EVALUATION MATRIX, 2021 185
11.8 COMPETITIVE BENCHMARKING 186
11.8.1 OVERALL COMPANY FOOTPRINT 186
TABLE 184 OVERALL COMPANY FOOTPRINT (17 COMPANIES) 186
TABLE 185 COMPANY FOOTPRINT: BY TYPE (17 COMPANIES) 187
TABLE 186 COMPANY FOOTPRINT: BY REGION (17 COMPANIES) 188
11.9 COMPETITIVE SCENARIO 188
11.9.1 DEALS 189
TABLE 187 DEALS, JANUARY 2019–FEBRUARY 2022 189
11.9.2 OTHER DEVELOPMENTS 189
TABLE 188 OTHER DEVELOPMENTS, JANUARY 2019–FEBRUARY 2022 189
12 COMPANY PROFILES 190
12.1 KEY PLAYERS 190
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 DANAHER CORPORATION (PALL CORPORATION AND CYTIVA LIFE SCIENCE) 190
TABLE 189 DANAHER CORPORATION: BUSINESS OVERVIEW 190
FIGURE 31 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 191
12.1.2 SARTORIUS STEDIM BIOTECH 195
TABLE 190 SARTORIUS STEDIM BIOTECH: BUSINESS OVERVIEW 195
12.1.3 MERCK KGAA 199
TABLE 191 MERCK KGAA: BUSINESS OVERVIEW 199
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2020) 200
12.1.4 AHLSTROM-MUNKSJÖ 204
TABLE 192 AHLSTROM-MUNKSJÖ: BUSINESS OVERVIEW 204
FIGURE 34 AHLSTROM-MUNKSJÖ: COMPANY SNAPSHOT (2020) 205
12.1.5 ADVANCED MICRODEVICES PVT. LTD. 208
TABLE 193 ADVANCED MICRODEVICES PVT. LTD.: BUSINESS OVERVIEW 208
12.1.6 DCN DIAGNOSTICS 210
TABLE 194 DCN DIAGNOSTICS: BUSINESS OVERVIEW 210
12.2 OTHER PLAYERS 211
12.2.1 FORTIS LIFE SCIENCES 211
TABLE 195 FORTIS LIFE SCIENCES: BUSINESS OVERVIEW 211
12.2.2 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD 212
TABLE 196 HANGZHOU COBETTER FILTRATION EQUIPMENT CO. LTD.:
BUSINESS OVERVIEW 212
12.2.3 AXIVA SICHEM BIOTECH 214
TABLE 197 AXIVA SICHEM BIOTECH: BUSINESS OVERVIEW 214
12.2.4 NUPORE FILTRATION SYSTEM 216
TABLE 198 NUPORE FILTRATION SYSTEM: BUSINESS OVERVIEW 216
12.2.5 BALLYA BIO 217
TABLE 199 BALLYA BIO: BUSINESS OVERVIEW 217
12.2.6 RUNBIO BIOTECH CO. LTD. 219
TABLE 200 RUNBIO BIOTECH CO. LTD.: BUSINESS OVERVIEW 219
12.2.7 NEENAH GESSNER 220
TABLE 201 NEENAH GESSNER: BUSINESS OVERVIEW 220
12.2.8 MAXIM BIOMEDICAL 221
TABLE 202 MAXIM BIOMEDICAL: BUSINESS OVERVIEW 221
12.2.9 CYTODIAGNOSTICS 222
TABLE 203 CYTODIAGNOSTICS: BUSINESS OVERVIEW 222
12.2.10 SENOVA GMBH 223
TABLE 204 SENOVA GMBH: BUSINESS OVERVIEW 223
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX 224
13.1 DISCUSSION GUIDE 224
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 229
13.3 AVAILABLE CUSTOMIZATIONS 231
13.4 RELATED REPORTS 231
13.5 AUTHOR DETAILS 232

US Healthcare Environmental Services Market by Type (Janitorial/Core-Cleaning, Infection Control & Prevention, Front-of-house cleaning & Brand Experie...

Publisher:        MarketsandMarkets

# of Pages:        126

Rating: 

1 User License $4,950

Publication Date:  March, 2022

Price:       $4,950 / User License




1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION & SCOPE 15
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 16
1.2.2 MARKET SEGMENTATION 16
FIGURE 1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET SEGMENTATION 16
1.2.3 YEARS CONSIDERED FOR THE STUDY 17
1.3 CURRENCY 17
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 17
1.4 STAKEHOLDERS 18
2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
FIGURE 2 RESEARCH DESIGN 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 21
2.1.2 PRIMARY RESEARCH 21
FIGURE 3 PRIMARY SOURCES 22
2.1.2.1 Key data from primary sources 23
2.1.2.2 Insights from primary experts 23
2.1.2.3 Breakdown of primary interviews 24
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE (SUPPLY & DEMAND SIDE) AND DESIGNATION 24
2.2 MARKET SIZE ESTIMATION 25
FIGURE 5 MARKET SIZE APPROACH – REVENUE SHARE ANALYSIS 25
FIGURE 6 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 26
FIGURE 7 DEMAND-SIDE APPROACH 28
2.3 DATA TRIANGULATION 29
FIGURE 8 DATA TRIANGULATION METHODOLOGY 29
2.4 MARKET RANKING ANALYSIS 30
2.5 ASSUMPTIONS FOR THE STUDY 30
2.6 LIMITATIONS 31
2.6.1 METHODOLOGY-RELATED LIMITATIONS 31
2.6.2 SCOPE-RELATED LIMITATIONS 31
2.7 RISK ASSESSMENT 31
TABLE 2 RISK ASSESSMENT: US HEALTHCARE ENVIRONMENTAL SERVICES MARKET 31
 
3 EXECUTIVE SUMMARY 32
FIGURE 9 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2021 VS. 2026 (USD MILLION) 32
FIGURE 10 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET,
BY FACILITY TYPE, 2021 VS. 2026 (USD MILLION) 33
4 PREMIUM INSIGHTS 34
4.1 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET OVERVIEW 34
FIGURE 11 STRINGENT REGULATORY GUIDELINES ON INFECTION CONTROL & PREVENTION METHODS IS A KEY FACTOR DRIVING THE MARKET GROWTH 34
4.2 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE AND FACILITY TYPE 35
FIGURE 12 JANITORIAL/CORE-CLEANING SERVICES ACCOUNTED FOR THE LARGEST SHARE OF THE US HEALTHCARE ENVIRONMENTAL SERVICES
MARKET IN 2020 35
4.3 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE (2021–2026) 36
FIGURE 13 ACUTE CARE FACILITIES TO DOMINATE THE US HEALTHCARE ENVIRONMENTAL SERVICES MARKET DURING THE FORECAST PERIOD 36
5 MARKET OVERVIEW 37
5.1 INTRODUCTION 37
5.2 MARKET DYNAMICS 37
TABLE 3 MARKET DYNAMICS: HEALTHCARE ENVIRONMENTAL SERVICES MARKET 37
5.2.1 MARKET DRIVERS 38
5.2.1.1 Increasing prevalence of Hospital-acquired infections (HAIs) 38
5.2.1.2 Rising number of hospital admissions and surgeries 39
TABLE 4 US: PERCENTAGE INCREASE IN THE NUMBER OF SURGERIES PERFORMED 39
FIGURE 14 TOTAL ADMISSIONS IN ALL US HOSPITALS 40
FIGURE 15 TOTAL NUMBER OF HOSPITALS IN THE US 40
5.2.1.3 Shortage of in-house expertise and the rising need to reduce healthcare costs 41
5.2.1.4 Increasing outsourcing of cleaning services 41
5.2.2 MARKET RESTRAINTS 41
5.2.2.1 Healthcare facilities with an in-house EVS department 41
5.2.3 MARKET OPPORTUNITIES 42
5.2.3.1 Sustained acquisitions among strategic & financial buyers 42
TABLE 5 COMPANY ACQUISITIONS 42
5.2.4 MARKET CHALLENGES 42
5.2.4.1 Noncompliance with cleaning standards by EVS providers 42
5.3 INDUSTRY TRENDS 43
5.3.1 EMERGENCE OF NEW SURFACE DISINFECTANTS &
GREEN CLEANING PRODUCTS 43
5.3.2 DISINFECTION ROBOTS 44
5.3.3 MONITORING TOOLS FOR CLEANING QUALITY ASSESSMENT 44
5.4 TECHNOLOGY ANALYSIS 45
TABLE 6 TECHNOLOGY INNOVATION IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 45
5.5 PATENT ANALYSIS 45
5.5.1 PATENT PUBLICATION TRENDS FOR HEALTHCARE ENVIRONMENTAL SERVICES 46
FIGURE 16 PATENT PUBLICATION TRENDS (JANUARY 2011–DECEMBER 2021) 46
5.5.2 JURISDICTION AND TOP APPLICANT ANALYSIS 47
FIGURE 17 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 47
FIGURE 18 TOP APPLICANT COUNTRIES/REGIONS FOR HEALTHCARE ENVIRONMENTAL SERVICES PATENTS (JANUARY 2011–JANUARY 2022) 48
TABLE 7 LIST OF PATENTS/PATENT APPLICATIONS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET, 2020–2021 48
5.6 IMPACT OF COVID-19 ON THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 50
6 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE 51
6.1 INTRODUCTION 52
TABLE 8 US: HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY TYPE,
2019–2026 (USD MILLION) 52
6.2 JANITORIAL SERVICES/CORE-CLEANING SERVICES 52
6.2.1 MANDATORY REGULAR CLEANING AND DISINFECTION OF HEALTHCARE FACILITIES TO DRIVE THE MARKET GROWTH 52
6.3 INFECTION PREVENTION & CONTROL SERVICES 53
TABLE 9 US: INFECTION PREVENTION & CONTROL SERVICE MARKET, BY TYPE,
2019–2026 (USD MILLION) 53
6.3.1 SPECIALIZED CLEANING SERVICES 53
6.3.1.1 Rising adoption of specialized services to reduce HAIs to drive the market growth 53
6.3.2 INFECTION PREVENTION & CONTROL CONSULTATION SERVICES 53
6.3.2.1 The provision of customized environmental services specific
to a healthcare facility ensures market demand 53
6.4 ENHANCED CLEANING TECHNOLOGY 54
6.4.1 RISING DEMAND FOR ADVANCED CLEANING SOLUTIONS TO DRIVE THE SEGMENT GROWTH 54
TABLE 10 EXAMPLES OF COMPANIES PROVIDING TECHNOLOGY & INNOVATION IN HEALTHCARE EVS 54
6.5 FRONT-OF-HOUSE CLEANING AND BRAND EXPERIENCE 56
6.5.1 RISING AWARENESS TOWARDS A CLEAN AND SAFE ENVIRONMENT DURING PANDEMICS TO SUSTAIN THE MARKET GROWTH 56
6.6 OTHER SERVICES 56
 
7 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE 57
7.1 INTRODUCTION 58
FIGURE 19 STATES WITH THE HIGHEST NUMBER OF COVID-19 ADMISSIONS
(FEBRUARY 2022) 58
TABLE 11 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET, BY FACILITY TYPE, 2019–2026 (USD MILLION) 59
7.2 ACUTE-CARE FACILITIES 59
TABLE 12 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR ACUTE-CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 59
7.2.1 ACUTE HOSPITALS 60
7.2.1.1 Increasing hospital admissions due to COVID-19 and the rising prevalence of HAIs propel the market growth 60
FIGURE 20 NUMBER OF HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS
IN THE US (2020) 60
FIGURE 21 HAIS REPORTED BY GENERAL ACUTE CARE HOSPITALS IN THE US (2020) 61
FIGURE 22 HAIS REPORTED BY CRITICAL ACCESS HOSPITALS (CAHS) IN THE US (2018) 61
7.2.2 MILITARY TREATMENT FACILITY 61
7.2.2.1 The increasing number of military ambulatory health services & funding to drive the market growth 61
FIGURE 23 MILITARY HEALTH SYSTEMS FACILITIES IN THE US (2021) 62
7.2.3 CHILDREN’S HOSPITALS 62
7.2.3.1 Rising cases of COVID-19 and infection-related mortality rates among children drive the market growth 62
7.2.4 AMBULATORY SURGERY CENTERS (ASCS) 63
7.2.4.1 ASCs save time and reduce the risk of HAIS; key factor driving the market growth 63
FIGURE 24 US SURGERY CASES BY SETTING: ASC VS. HOPD (2005-2020) 64
7.2.5 ACADEMIC MEDICAL CENTERS (AMCS) 64
7.2.5.1 Healthcare capacity expansion during COVID-19 drives the adoption of healthcare environmental services in AMCs 64
7.3 POST-ACUTE CARE FACILITIES 64
TABLE 13 US: HEALTHCARE ENVIRONMENTAL SERVICES FOR POST-ACUTE CARE SETTINGS, BY TYPE 2019–2026 (USD MILLION) 65
7.3.1 LONG-TERM ACUTE HOSPITALS (LTACH) 65
7.3.1.1 Increasing risk of infection due to prolonged hospital stays to drive the market growth 65
7.3.2 SKILLED NURSING FACILITIES (SNF) 66
7.3.2.1 Increasing admissions of elderly people in skilled nursing facilities to drive the market growth 66
7.3.3 OTHER POST-ACUTE CARE FACILITIES 66
7.4 NON-ACUTE CARE FACILITIES 67
TABLE 14 US: ENVIRONMENTAL SERVICES MARKET FOR NON-ACUTE CARE SETTINGS, BY TYPE, 2019–2026 (USD MILLION) 67
7.4.1 PHYSICIAN’S OFFICES AND CLINICS 67
7.4.1.1 High patient traffic leads to continuous cleaning & maintenance to drive the market growth 67
7.4.2 OTHER NON-ACUTE CARE FACILITIES 68
FIGURE 25 DISTRIBUTION OF INDUSTRY MEDICAL AND HEALTH R&D INVESTMENTS,
BY SEGMENT (2020) 68
8 COMPETITIVE LANDSCAPE 70
8.1 OVERVIEW 70
8.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 70
8.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE HEALTHCARE ENVIRONMENTAL SERVICES MARKET 71
8.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS 72
8.4 MARKET RANKING ANALYSIS 73
FIGURE 27 US HEALTHCARE ENVIRONMENTAL SERVICE MARKET RANKING,
BY KEY PLAYER, 2020 73
8.5 COMPETITIVE BENCHMARKING 75
TABLE 15 FOOTPRINT OF COMPANIES IN THE HEALTHCARE ENVIRONMENTAL
SERVICES MARKET 75
TABLE 16 SERVICE FOOTPRINT OF COMPANIES 76
TABLE 17 END-USER FOOTPRINT OF COMPANIES 77
8.6 COMPETITIVE LEADERSHIP MAPPING 77
8.6.1 STARS 78
8.6.2 EMERGING LEADERS 78
8.6.3 PERVASIVE PLAYERS 78
8.6.4 PARTICIPANTS 78
FIGURE 28 US HEALTHCARE ENVIRONMENTAL SERVICES MARKET:
COMPETITIVE LEADERSHIP MAPPING (2021) 79
8.7 COMPETITIVE SCENARIO 80
8.7.1 SERVICE APPROVALS/ENHANCEMENTS 80
8.7.2 DEALS 81
TABLE 19 DEALS, 2018–2022 81
8.7.3 OTHER DEVELOPMENTS 82
9 COMPANY PROFILES 83
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
9.1 SODEXO GLOBAL 83
TABLE 21 SODEXO GLOBAL: BUSINESS OVERVIEW 83
FIGURE 29 SODEXO GLOBAL: COMPANY SNAPSHOT (2021) 84
9.2 COMPASS GROUP (CROTHALL HEALTHCARE (US)) 87
TABLE 22 COMPASS GROUP: BUSINESS OVERVIEW 87
FIGURE 30 COMPASS GROUP: COMPANY SNAPSHOT (2021) 88
 
9.3 ARAMARK CORPORATION 90
TABLE 23 ARAMARK CORPORATION: BUSINESS OVERVIEW 90
FIGURE 31 ARAMARK CORPORATION: COMPANY SNAPSHOT (2021) 91
9.4 HOSPITAL HOUSEKEEPING SYSTEMS (HHS) (US) 94
TABLE 24 HOSPITAL HOUSEKEEPING SYSTEMS (HHS): BUSINESS OVERVIEW 94
9.5 HEALTHCARE SERVICES GROUP, INC. 97
TABLE 25 HEALTHCARE SERVICES GROUP, INC.: BUSINESS OVERVIEW 97
FIGURE 32 HEALTHCARE SERVICES GROUP: COMPANY SNAPSHOT (2020) 98
9.6 ABM INDUSTRIES INCORPORATED 100
TABLE 26 ABM INDUSTRIES INCORPORATED: BUSINESS OVERVIEW 100
FIGURE 33 ABM INDUSTRIES INCORPORATED: COMPANY SNAPSHOT (2020) 101
9.7 OCTOCLEAN 103
TABLE 27 OCTOCLEAN: BUSINESS OVERVIEW 103
9.8 SERVICEMASTER CLEAN (SERVICEMASTER TBS) 105
TABLE 28 SERVICEMASTER CLEAN.: BUSINESS OVERVIEW 105
9.9 CORVUS JANITORIAL SYSTEMS 107
TABLE 29 CORVUS JANITORIAL SYSTEMS: BUSINESS OVERVIEW 107
9.10 BRAVO! BUILDING SERVICES 109
TABLE 30 BRAVO! BUILDING SERVICES: BUSINESS OVERVIEW 109
9.11 POWERLINK ENVIRONMENTAL SERVICES, LLC 111
TABLE 31 POWERLINK ENVIRONMENTAL SERVICES, LLC: BUSINESS OVERVIEW 111
9.12 JANI-KING INTERNATIONAL, INC. 112
TABLE 32 JANI- KING INTERNATIONAL, INC: BUSINESS OVERVIEW 112
9.13 AVI FOOD SYSTEMS(US) 114
TABLE 33 AVI FOOD SYTEMS, INC.: BUSINESS OVERVIEW 114
9.14 SERVICON 115
TABLE 34 SERVICON: BUSINESS OVERVIEW 115
9.15 XANITOS, INC. 117
TABLE 35 XANITOS, INC.: BUSINESS OVERVIEW 117
9.16 STATHAKIS 119
TABLE 36 STATHAKIS: BUSINESS OVERVIEW 119
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
10 APPENDIX 120
10.1 INSIGHTS FROM INDUSTRY EXPERTS 120
10.2 DISCUSSION GUIDE 121
10.3 KNOWLEDGESTORE: MARKETSANDMARKETS SUBSCRIPTION PORTAL 124
10.4 AVAILABLE CUSTOMIZATIONS 126
10.5 RELATED REPORTS 126
10.6 AUTHOR DETAILS 127